CBD Life Sciences Inc. (CBDL)
OTCMKTS · Delayed Price · Currency is USD
0.0002
-0.0001 (-33.33%)
Jul 27, 2026, 10:08 AM EST
CBD Life Sciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.33 | 0.01 | 0 | 0 | 1.03 |
Cash & Short-Term Investments | 0.33 | 0.01 | 0 | 0 | 1.03 |
Cash Growth | 4963.34% | 160.29% | 350.90% | -99.95% | 25862.97% |
Other Receivables | 0.22 | 0.2 | - | - | - |
Receivables | 0.22 | 0.2 | - | - | - |
Inventory | 0.04 | 0.03 | 0.02 | 0.01 | 0.05 |
Total Current Assets | 0.58 | 0.24 | 0.02 | 0.01 | 1.07 |
Property, Plant & Equipment | - | 0.03 | 0.09 | 0.16 | 0.19 |
Long-Term Investments | 0.1 | - | - | - | - |
Goodwill | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Other Intangible Assets | - | 0.01 | 0.03 | 0.03 | - |
Other Long-Term Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 0.79 | 0.39 | 0.24 | 0.3 | 1.36 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.03 | - | - | - | - |
Accrued Expenses | 0.01 | 0.01 | 0.02 | - | - |
Other Current Liabilities | - | - | 0.18 | 0.17 | - |
Total Current Liabilities | 0.04 | 0.01 | 0.2 | 0.17 | - |
Other Long-Term Liabilities | - | - | - | - | 0.03 |
Total Liabilities | 0.04 | 0.01 | 0.2 | 0.17 | 0.03 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 4.65 | 4.37 | 4.07 | 4.07 | 4.07 |
Additional Paid-In Capital | 11.42 | 11.28 | 10.48 | 10.48 | 10.82 |
Retained Earnings | -15.37 | -15.32 | -14.56 | -14.48 | -13.62 |
Comprehensive Income & Other | -0.02 | -0.02 | -0.01 | - | - |
Total Common Equity | 0.68 | 0.31 | -0.02 | 0.07 | 1.27 |
Shareholders' Equity | 0.75 | 0.37 | 0.04 | 0.13 | 1.33 |
Total Liabilities & Equity | 0.79 | 0.39 | 0.24 | 0.3 | 1.36 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 0.33 | 0.01 | 0 | 0 | 1.03 |
Net Cash Growth | 4963.34% | 160.29% | 350.90% | -99.95% | 25862.97% |
Net Cash Per Share | 0.00 | 0.00 | 0.00 | - | 0.01 |
Filing Date Shares Outstanding | 5,932 | 641.7 | 141.69 | 135.69 | 135.69 |
Total Common Shares Outstanding | 5,932 | 641.7 | 141.69 | 135.69 | 135.69 |
Working Capital | 0.54 | 0.23 | -0.18 | -0.16 | 1.07 |
Book Value Per Share | 0.00 | 0.00 | -0.00 | 0.00 | 0.01 |
Tangible Book Value | 0.58 | 0.2 | -0.15 | -0.06 | 1.17 |
Tangible Book Value Per Share | 0.00 | 0.00 | -0.00 | -0.00 | 0.01 |
Machinery | - | - | - | - | 0.01 |
Leasehold Improvements | - | - | - | - | 0.15 |